Myriad Genetics INC Form 4 insider transactions

NASDAQ
Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports the acquisition of 6,468 shares of common stock on February 7, 2025, related to performance-based restricted stock units.
NASDAQ
Chief Technology Officer Kevin Richard Haas reports acquisition and disposal of Myriad Genetics stock and performance-based restricted stock units.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, acquired 10,622 shares of common stock on February 7, 2025, through the vesting of performance-based restricted stock units.
NASDAQ
Mark Verratti, Chief Commercial Officer of Myriad Genetics, acquired 12,758 shares of common stock on February 7, 2025, following the vesting of performance-based restricted stock units (PSUs).
NASDAQ
Paul J. Diaz, President and CEO of Myriad Genetics, acquired 114,828 shares of common stock on February 7, 2025, following the vesting of performance-based restricted stock units (PSUs).
NASDAQ
Shereen Solaiman, Chief People Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports the disposal of 2,697 shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Chief Technology Officer Kevin Richard Haas of Myriad Genetics Inc. reports the withholding of 1,016 common stock shares to cover tax obligations related to vesting restricted stock units on February 25, 2025.
NASDAQ
Scott Leffler, CFO of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Myriad Genetics' Chief Scientific Officer, Dale Muzzey, sold 417 shares of common stock on January 1, 2025, to cover tax obligations related to vesting restricted stock units.
NASDAQ
Myriad Genetics' Chief Operating Officer, Samraat S. Raha, sold shares to cover tax obligations related to vested restricted stock units.
NASDAQ
Myriad Genetics Inc. executive Mark Steven Davis was granted 22,816 restricted stock units under the company's 2017 equity incentive plan.
NASDAQ
Myriad Genetics Chief Operating Officer, Samraat S. Raha, acquired 1,118 shares of common stock through the company's employee stock purchase plan.
NASDAQ
Paul J. Diaz, President and CEO of Myriad Genetics, sold 15,000 shares of common stock on October 11, 2024, at a price of $22.93 per share.
NASDAQ
Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, sold 452 shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Chief Technology Officer Kevin Richard Haas of Myriad Genetics Inc. reports disposition of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Mark Verratti, Chief Commercial Officer of Myriad Genetics, sold 1,075 shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, disposed of 966 shares of common stock on September 21, 2024, to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of 964 shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Myriad Genetics CEO Paul J. Diaz sold 15,000 shares of common stock at a price of $26.72 per share on September 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, sold 2,100 shares of common stock on September 11, 2024, at a price of $26.172 per share.
NASDAQ
Director Heinrich Dreismann sold 10,000 shares of Myriad Genetics Inc. on September 9, 2024, at an average price of $27.052 per share.
NASDAQ
Jennifer Lynne Fox, Chief Legal Officer of Myriad Genetics, reports the acquisition of 61,771 restricted stock units.
NASDAQ
Director Colleen F. Reitan sold 4,6012 shares of Myriad Genetics Inc. common stock at a weighted average price of $27.946 per share on September 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of 217 common stock shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, sold 11,538 shares of common stock at $27.82 per share on August 21, 2024.
NASDAQ
Director Rashmi Kumar sold 7,500 shares of Myriad Genetics Inc. on August 19, 2024, at a price of $28.01 per share, according to a Form 4 filing.
NASDAQ
Paul J. Diaz, President and CEO of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Director Daniel Skovronsky reports acquisition of Myriad Genetics restricted stock units.